Defining the immunogenic landscape of early mosquito-stage P. Falciparum to accelerate malaria transmission-blocking vaccine discovery

Active Grant Awarded Last action

Award ID
R01AI183678
Recipient
Awarding agency
Obligated
$2,865,844

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 49% complete
Place of performance
Seattle, WA 98109, USA

Award details come from USAspending.gov.

Description

Abstract
The disease malaria is caused by vector-borne parasites of the genus plasmodium. With hundreds of millions of infections and over half a million deaths annually, malaria remains one of the foremost global health challenges. The two who-recommended malaria vaccines have only moderate efficacy against severe disease and do not provide sterilizing protection, neither do they prevent transmission of the parasite to the mosquito vector that carries IT between human hosts. The majority of vaccine development efforts to date have focused on means to prevent infection of humans. However, a comprehensive malaria eradication effort also requires blocking transmission with vector-targeted interventions. Compared with vaccines that prevent infection by targeting pre- erythrocytic and asexual blood stages of the parasite, very few candidate antigens have been identified for transmission-blocking vaccines (TBVS) that target the transmitted forms of the parasite present in the mosquito vector stages. This disparity arises in part because the comprehensive characterization of protein expression that informs vaccines against pre-erythrocytic and asexual blood stages has not been performed for the stages that develop in the mosquito midgut, i.e., gametes, zygotes, and ookinetes. The few TBV candidates that have entered clinical trials, including PFS25, PFS48/45, and PFS230, are surface-exposed on these early mosquito-stage parasites. Importantly, IT has been demonstrated that antibodies against these proteins can be generated in the vertebrate host, carried to the mosquito vector in the blood meal, and subsequently interfere with fertilization and/or successful infection of the mosquito. We hypothesize that early mosquito-stage parasites exhibit many more undiscovered surface-exposed proteins, and that these proteins can be targeted by antibodies to prevent transmission of the malaria parasite to the mosquito vector. We will use mass spectrometry-based proteomics to provide the first comprehensive catalog of surface-exposed proteins in P. Falciparum gametes, zygotes, and ookinetes. In parallel, we will immunize animals with early mosquito-stage parasites and identify parasite proteins that elicit an immune response. From the subset of immunogenic surface-exposed parasite proteins, we will identify the most promising TBV candidates and evaluate them as antigens for transmission-blocking vaccines by quantifying the ability of antibodies against these antigens to prevent P. Falciparum from infecting mosquitoes.

Transactions

Action Obligated Date
Amendment $947,948
Amendment $947,948
Amendment $94,793
Original award $875,155

Subawards

Subrecipient Amount Awarded
Seattle Children's Hospital Dr. Vaughan will supervise all activities at Seattle Children’s Research Institute. Dr. Vaughan’s team, mostly, Dr. Bhagyashree Deshmukh, Ph.D., will be… $341,125
University Of Maryland, Baltimore During the reporting period, we established ring-stage parasite transfection by electroporation. We designed and produced the construct necessary to generate… $35,170
University Of South Florida The Sather laboratory will be responsible for the design, production, and biochemical characterization of novel surface antigens. Successful antigens will be… $294,154
Seattle Children's Hospital Dr. Vaughan will supervise all activities at Seattle Children’s Research Institute. Dr. Vaughan’s team, mostly, Dr. Bhagyashree Deshmukh, Ph.D., will be… -$35,170
University Of South Florida The Sather laboratory will be responsible for the design, production, and biochemical characterization of novel surface antigens. Successful antigens will be… $135,696
Seattle Children's Hospital Dr. Vaughan will conduct activities at Seattle Children’s Research Institute. Dr. Vaughan's lab will be responsible for carrying out all immunization… -$135,696
Seattle Children's Hospital Drs. Sather and Kappe will conduct their activities at Seattle Children’s Research Institute. Dr. Sather is PD/PI on this proposal, as well as the subcontract… $680,339
Seattle Children's Hospital Dr. Sather's lab will be responsible for carrying out all immunization campaigns and assessments of vaccine-induced antibody responses. As protein candidates… $612,306

Quick answers

Who received award R01AI183678?

R01AI183678 was awarded to Institute For Systems Biology by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 5, 2024.

How much is award R01AI183678 worth?

$2,865,844 has been obligated on R01AI183678.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award